Bank of Montreal’s Stemline Therapeutics, Inc. STML Stock Holding History

Bank of Montreal’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,841	Closed	-$62K	–	5051
2019 Q4	$62K	Buy	5,841 +1,909	+49%	+$19K	﹤0.01%	3743
2019 Q3	$41K	Buy	3,932 +561	+17%	+$7.34K	﹤0.01%	3727
2019 Q2	$52K	Buy	+3,371	New	+$48.8K	﹤0.01%	3674
2019 Q1	–	Sell	-406	Closed	-$4K	–	4989
2018 Q4	$4K	Buy	406 +210	+107%	+$2.72K	﹤0.01%	4208
2018 Q3	$3K	Hold	196	–	–	﹤0.01%	4295
2018 Q2	$3K	Buy	+196	New	+$3.5K	﹤0.01%	4297
2017 Q1	–	Sell	-6,836	Closed	-$90K	–	4287
2016 Q4	$90K	Buy	6,836 +1,358	+25%	+$16.4K	﹤0.01%	2888
2016 Q3	$60K	Buy	+5,478	New	+$44.5K	﹤0.01%	2992
2014 Q3	–	Sell	-240	Closed	-$4K	–	4588
2014 Q2	$4K	Buy	+240	New	+$3.68K	﹤0.01%	4309

Other funds holding STML

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Bank of Montreal's STML Position: Q1 2020 in Review

Bank of Montreal sold out of Stemline Therapeutics, Inc. (STML) in Q1 2020, closing a stake of 5,841 shares — an estimated $62K sold.

Bank of Montreal first reported a position in STML in Q2 2014 and held it in 9 quarters. The position peaked at $90K in Q4 2016. 94 funds tracked by Wall St. Rank hold STML as of Q1 2020.

Bank of Montreal reported no remaining Stemline Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
Bank of Montreal sold 5,841 Stemline Therapeutics, Inc. shares in Q1 2020, an estimated $62K.
Bank of Montreal first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and held it in 9 quarters.
Bank of Montreal's Stemline Therapeutics, Inc. position peaked at $90K in Q4 2016.
94 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q1 2020.

Based on Bank of Montreal's 13F filing for Q1 2020, filed 13 May 2020.